CellSource Co., Ltd.
セルソース株式会社 2026年10月期 第3四半期決算説明資料
Revenue declined year over year, including a revision of the full-year outlook. Indicates segment contributions and improvements in cost structure. Contributions from AI-related and exosome-related businesses and others varied versus the previous period.
Key Figures
- 売上高: 2,557 百万円（前年同月比 -9.2%）
- 営業利益: 179 百万円（前年同月比 +45.3%）
- 売上総利益率: 58.9%〜59.6%程度（+1.3pt）
AI要約
業績の概要
For the third quarter of the fiscal year ending October 2026, revenue was flat to slightly down versus the previous period, while operating income improved significantly. Key drivers are cost control and productivity improvements. Contributions from certain segments, such as self-funded orthopedic care and exosome-related businesses, varied versus the prior period. The company’s overall revenue mix remains diversified, with cosmetics sales appearing as a headwind.
今後の見通しと資本政策
The outlook includes potential revisions to full-year earnings; explanations of key measures and progress, particularly in contract processing services, medical device sales, and PAJUU, outlining growth strategies. Ongoing progress in new businesses and cost-reduction efforts are expected to support profit improvement in the next period.
セルソース株式会社
Company overview · Stock price · Financial data · All IR
